Iressa NSCLC Phase III stopped

Researchers stopped a National Cancer Institute-sponsored U.S. Phase III trial of Iressa gefitinib from AstraZeneca (LSE:AZN; AZN) to treat non-small cell lung cancer (NSCLC) after an interim review showed the compound would not improve survival, the primary endpoint. The S0023 study in 672 patients compared chemotherapy and radiation followed by either Taxotere docetaxel plus Iressa or Taxotere plus placebo. Data from the study will be presented in May at the American Society of Clinical Oncology meeting in Orlando. Taxotere is marketed by sanofi-aventis (Euronext:SAN; SNY). ...